Abstract: The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims.

Abstract: A data backup system is provided for backing up data files from a data source and for securing those data files against accidental modification or deletion. The system comprises storage and a data protection component that includes an application programming interface defining a command set. The system can also comprise a backup application that is configured to use the commands of the command set. The data protection component allows applications that use the commands of the command set, such as the backup application, to access the storage of the system. The data protection component prevents operating systems and applications that do not use the commands of the command set from accessing the storage. The data protection function of the data protection component can optionally be disabled to allow open access to the storage.

Abstract: A peripheral electronic device includes a health check application configured to execute automatically upon connection of the peripheral device to a data source, such as a personal computer. The health check application can diagnose problems and if necessary, repair the problems with the peripheral device, the data source, or both. Examples of problems include corrupted data and indications of software, firmware, and hardware failures or impending failures. In some instances, the health check application can provide a warning of an impending failure. The health check application, after initially executing, can be triggered in various ways to scan again for problems. In addition to finding and repairing problems, the health check application can also attend to maintenance.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ?C(R1)— or ?N—; R1 is hydrogen or an optional substituent and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2—, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; R3 is a radical of formula -(Alk1)m-(Z)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z is —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(?O)—, —O—(C?O)—, —C(?O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic heterocyclic radical having 5 to 10 ring atoms; Alk1 and Alk2 are optionally substituted C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, or —N(CH2CH3)—; and Q is hydrogen, halogen, nit

Abstract: A portable data map of a data source is created using metadata obtained from the data source. The created data map represents the entire data set of the data source and can be carried on a mobile device without having to carry the entire data set and thus requiring much less storage space. A user of the mobile device can navigate this data map and view the file/folder hierarchy of the data source even when the mobile device is off line or not currently in communication with the data source. Once a user has made a selection the actual file(s) can be downloaded to the mobile device.

Abstract: A data backup system is provided that when coupled to a data source, such as a personal computer, and a media player, such an Apple Computer IPod media player, the data backup system blocks certain communications between the data source and the media player thus preventing the data source from recognizing the media player as such thereby avoiding the launching of synchronization software for the media player, the data backup system also causing the automatic launching of a backup application stored on the data backup system so that data files can be located on the data source and then backed up to the media player.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: A software application is provided for a user to select a backed up data file and specify a task to be performed by an online service provider on the selected file. The application automatically connects to the online service provider and uploads the selected file for the online service provider to perform the task. Tasks that can be performed include printing, sharing, viewing, playing and archiving the selected file. Task preferences, user settings and user information can also be specified by the user and uploaded to the online service provider. Automatic connection to the online service provider can be via default setting, selected file type, or specified task. Alternatively, the user can designate which service provider is to perform the task. Payment for the task can be accomplished via bundled credits or by other payment mechanisms.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims.

Abstract: A data backup system is provided for backing up data files from a data source and for securing those data files against accidental modification or deletion. The system comprises storage and a data protection component that includes an application programming interface defining a command set. The system can also comprise a backup application that is configured to use the commands of the command set. The data protection component allows applications that use the commands of the command set, such as the backup application, to access the storage of the system. The data protection component prevents operating systems and applications that do not use the commands of the command set from accessing the storage. The data protection function of the data protection component can optionally be disabled to allow open access to the storage.

Abstract: Systems and methods are provided for controlling the number of products produced by contract manufacturers in order to prevent unauthorized overproduction. Each authorized device that is produced includes both a serial number and an encryption of the serial number. Each device is configured to decrypt the encrypted serial number and verify the decrypted serial number matches the serial number before the device will function properly. The encryption of the serial number is performed at a secure location outside of the control of the manufacturer, and the encrypted serial number is then transmitted to the manufacturer and stored to the device. Without knowledge of, or access to, the details of the encryption process, the manufacturer cannot independently produce devices with properly encrypted serial numbers. Accordingly, the number of properly functioning devices the manufacturer can produce can be limited by controlling the number of encrypted serial numbers provided to the manufacturer.

Abstract: A data backup system is provided for backing up data files from a data source and for securing those data files against accidental modification or deletion. The system comprises storage and a data protection component that includes an application programming interface defining a command set. The system can also comprise a backup application that is configured to use the commands of the command set. The data protection component allows applications that use the commands of the command set, such as the backup application, to access the storage of the system. The data protection component prevents operating systems and applications that do not use the commands of the command set from accessing the storage. The data protection function of the data protection component can optionally be disabled to allow open access to the storage.

Abstract: A software application is provided for a user to select a backed up data file and specify a task to be performed by an online service provider on the selected file. The application automatically connects to the online service provider and uploads the selected file for the online service provider to perform the task. Tasks that can be performed include printing, sharing, viewing, playing and archiving the selected file. Task preferences, user settings and user information can also be specified by the user and uploaded to the online service provider. Automatic connection to the online service provider can be via default setting, selected file type, or specified task. Alternatively, the user can designate which service provider is to perform the task. Payment for the task can be accomplished via bundled credits or by other payment mechanisms.

Abstract: A data backup system comprises an emulation component and a storage device having logical storage areas. The emulation component is configured to represent a first logical storage area of the storage device, such as a solid state memory or a disk drive partition, as if it were an auto-launch device. Accordingly, a data source, such as a personal computer, will interact with the first logical storage area as if it were the auto-launch device. As some operating systems are configured to recognize auto-launch devices upon connection and automatically execute applications stored thereon, merely connecting the data backup system to a data source running such an operating system can cause a backup application stored by the first logical storage area to automatically execute on the data source to selectively back up data to a second logical storage area of the storage device.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisi?q radiation.

Abstract: A software application is provided for a user to select a backed up data file and specify a task to be performed by an online service provider on the selected file. The application automatically connects to the online service provider and uploads the selected file for the online service provider to perform the task. Tasks that can be performed include printing, sharing, viewing, playing and archiving the selected file. Task preferences, user settings and user information can also be specified by the user and uploaded to the online service provider. Automatic connection to the online service provider can be via default setting, selected file type, or specified task. Alternatively, the user can designate which service provider is to perform the task. Payment for the task can be accomplished via bundled credits or by other payment mechanisms.

Abstract: Compounds of formula (IA) or (IB) have antibacterial activity: wherein W is ?C(H)— or ?N—; R3 is a radical of formula -(Alk1)m-(Z1)p-(Alk2)n-Q wherein m, p and n are independently 0 or 1, provided that at least one of m, p and n is 1, Z1 is —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, —N(CH2CH3)—, —C(—O)—, —O—(C?O)—, —C(?O)—O—, or an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 5 to 10 ring atoms; Alk1 and Alk2 are optionally substituted C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radicals, which may optionally terminate with or be interrupted by —O—, —S—, —S(O)—, —S(O2)—, —NH—, —N(CH3)—, Or —N(CH2CH3)—; and Q is hydrogen, halogen, nitrile, or hydroxyl, or an optionally substituted monocyclic carbocyclic or heterocyclic radical having 3 to 6 ring atoms; or an optionally substituted bicyclic carbocyclic or heterocyclic radical having 5 to 10 ring atoms; R